No Data
No Data
Accelerating recovery? In March, domestic Innovative Drugs investment and financing increased by about 50% year-on-year, and the Hong Kong Stock pharmaceutical Sector collectively surged.
① In March, domestic investment and financing for Innovative Drugs increased by approximately fifty percent year-on-year, how significant is the Bullish impact? ② The Hong Kong stock market's pharmaceutical Sector rose collectively, which stocks are attracting market attention?
CMS (00867.HK) recommends spinning off Demei Pharmaceutical and independently listing on the Main Board of the Hong Kong Stock Exchange.
On April 22, Globlue announced that CMS (00867.HK) proposed to spin off its subsidiary, DM Pharma, and list it independently on the Main Board of the Stock Exchange. The proposed spin-off (if it proceeds) is expected to be implemented through a distribution of all the DM Pharma shares held by the company to Shareholders in kind, with the distribution ratio calculated based on their respective shareholding proportions in the company as of the record date determined by the Board of Directors for the Shareholders' rights. According to Listing Rule Guidance Note 15, the independent listing of DM Pharma on the Stock Exchange constitutes a spin-off of the company from DM Pharma. The Stock Exchange has confirmed that the company can proceed with the establishment.
Express News | China Medical System Holdings - Proposed Spin-off and Separate Listing of Dermavon Holdings Limited
Hong Kong stocks in the pharmaceutical sector soared! Kai Medical surged more than 22%. Institutions claim that tariffs have "no impact" on the wave of Innovative Drugs going abroad.
① How do government policy support and the overseas expansion of Innovative Drugs become a new growth engine for Hong Kong stock pharmaceutical companies? ② Why does Zhongtai International believe that tariffs have limited impact on Innovative Drug companies?
The Medical sector has frequently issued Bullish policies, leading to a significant increase in the Hang Seng Yinhua CSI Innovative Drugs Industry ETF, Hang Seng Biotechnology ETF, Hang Seng Medical Index ETF, and Hong Kong Stock Connect Medical ETF.
Innovative Drugs and Medical stocks in Hong Kong surged, with INNOCARE, SIMCERE PHARMA, and ASCENTAGE-B rising over 12%; Lepu Biopharma-B, CMS, CSPC PHARMA, INNOVENT BIO, and Hutchmed (China) increased by more than 7%.
Shareholders May Be Wary Of Increasing China Medical System Holdings Limited's (HKG:867) CEO Compensation Package